TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04314297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib In Combination With Durvalumab
Description: At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers.
Study: NCT01393197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study: NCT01292057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole(up to 15 mg/day) for 8 days
Study: NCT01827423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical removal of sinonasal papiloma
Description: An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
Study: NCT00178776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model Group Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & Advice
Study: NCT04730661

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sit to stand test
Description: The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~* If SpO2 \<90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~* SpO2 \<90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~* SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge.
Study: NCT03114540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral
Study: NCT02831101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
Study: NCT01744535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Meal Mate (smartphone application)
Description: A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper food diary
Description: The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online food diary
Description: The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity.
Study: NCT02932371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECOM™.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-esophageal echography
Study: NCT02675673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GJ-Tube
Description: Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: G-Tube
Description: Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
Study: NCT02558413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA-C585 oral capsules
Description: BTA-C585; Single ascending doses from 50 mg to 800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BTA-C585 matching placebo
Description: Single ascending doses to match 50 to 800 mg BTA-C585 capsules
Study: NCT01158599

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IXIARO®
Description: IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
Study: NCT02543424

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor, cognitive and neuropsychological assessment
Description: Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor, cognitive and neuropsychological assessment
Description: Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
Study: NCT03344770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rESWT
Description: 5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rESWT
Description: 5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
Study: NCT01173289

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~* Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~* Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~* Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~* The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated.
Study: NCT03243292

Intervention type: OTHER
Intervention: Bronchial Thermoplasty
Description: patients had radio frequency ablation of the smooth muscle for asthma

Intervention type: OTHER
Intervention: Bronchial Thermoplasty
Description: patients had radio frequency ablation of the smooth muscle for asthma

Intervention type: OTHER
Intervention: Bronchial Thermoplasty
Description: patients had radio frequency ablation of the smooth muscle for asthma
Study: NCT00277654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: risperidone 0.5mg up to 4mg daily vs. placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: risperidone 0.5mg up to 4mg daily vs. placebo
Study: NCT02121119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
Study: NCT04122352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises (Rocabodo's 6x6 exercises and posture exercises)
Description: Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercises (Rocabodo's 6x6 exercises and posture exercises)
Description: Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
Study: NCT00611403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
Description: Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tears REFRESH ENDURA®
Description: REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
Study: NCT02604160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered by slow intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by slow intravenous (IV) infusion.
Study: NCT01511120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetraspan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetated Ringer's solution
Study: NCT02904213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ComBe Five (Liquid)
Study: NCT01292057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active drug Aripiprazole for 8 days
Study: NCT01265524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLP
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT00393575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
Study: NCT03349814

Intervention type: PROCEDURE
Intervention: Diagnostic laparoscopy without appendectomy
Description: A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.

Intervention type: PROCEDURE
Intervention: Diagnostic laparoscopy with appendectomy
Description: A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed

Intervention type: PROCEDURE
Intervention: Diagnostic laparoscopy with appendectomy
Description: A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
Study: NCT02247193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
Study: NCT01447108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)
Description: All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping.
Study: NCT04643717

Intervention type: OTHER
Intervention: Electronic pupillometer analysis
Description: Electronic pupillometer analysis
Study: NCT02284698

Intervention type: OTHER
Intervention: Health Education
Description: Heath education will be given through awareness creation \& pamphlet distribution

Intervention type: OTHER
Intervention: Health Education
Description: Heath education will be given through awareness creation \& pamphlet distribution
Study: NCT01137201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suturing of mesenteric defects
Study: NCT06010043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suturing of ileostomy using Dumpling suture method
Description: Suturing of ileostomy using Dumpling suture method

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Suturing of ileostomy using Traditional suture method
Description: Suturing of ileostomy using Traditional suture method
Study: NCT01745822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate
Description: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
Study: NCT00809302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered BID for about 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered BID for about 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered BID for about 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered BID for about 13 weeks
Study: NCT01043939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple Grape Juice
Description: 6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple Grape Juice
Description: 6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple Juice
Description: 6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple Juice
Description: 6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
Study: NCT03387527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate cancer decision aid
Description: Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
Study: NCT00271713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate, calcium and vitamin D
Description: 1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo,calcium and vitamin D
Description: 2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
Study: NCT02230514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-MT-OSTEO-ALPHA
Description: ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery

Intervention type: OTHER
Group type: OTHER
Intervention: autologous iliac crest
Description: Autologous iliac crest in association with surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Standard surgery for non-union fractures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard surgery for non-union fractures
Study: NCT00662675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrease MT 10.5, or MT 21
Description: Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Pancrease MT 10.5 or MT 21
Description: Capsules with Pancrease MT excipients without the active enzymes
Study: NCT02160899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-APO(a)Rx
Description: ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-APO(a)Rx
Description: ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-APO(a)Rx
Description: ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-APO(a)Rx
Description: ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
Study: NCT04952155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
Study: NCT03887702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive best practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Given PO
Study: NCT03293901

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
Study: NCT04254328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Description: Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT
Description: Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
Study: NCT06515808

Intervention type: DEVICE
Intervention: Direct Laryngoscope
Description: Patient receiving tracheal intubation with direct laryngoscope, GlideScope or Airway Scope
Study: NCT01643421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep inspiration and positive expiratory airway pressure
Description: It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
Study: NCT01089517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030 plus Lucentis
Description: once a month intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030 plus Lucentis
Description: once a month intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 10 mg/mL intravitreal injection monthly